Pharmaceutical Research and Technology Laboratories, Astellas Pharma Incorporated, 180 Ozumi, Yaizu, Shizuoka 425-0072, Japan.
Mol Pharm. 2023 Sep 4;20(9):4344-4353. doi: 10.1021/acs.molpharmaceut.3c00184. Epub 2023 Jul 31.
Optimization of the in vivo performance of dosage forms in humans is essential in developing not only conventional formulations but also drug delivery system (DDS) formulations. Although animal experiments are still useful for these formulations, in silico approaches have become increasingly important for DDS formulations with regard to species-specific differences in physiology that can affect the in vivo performance of dosage forms between animals and humans. Furthermore, it is also important to couple in vitro characterizations with in silico models to predict in vivo performance in humans precisely. In this review article, I summarized in vitro-in silico approaches to predicting the in vivo performance of oral DDS formulations (amorphous solid dispersions, lipid-based formulations, nanosized formulations, cyclodextrins-based formulations, sustained release products, enteric coat products, and orally disintegrating tablets) and parenteral DDS formulations (cyclodextrins-based formulations, liposomes, and inhaled formulations).
优化在体性能的剂型在人类中是必不可少的不仅在开发常规制剂而且药物传递系统(DDS)制剂。虽然动物实验仍然是有用的这些制剂,在计算机模拟方法已变得越来越重要的 DDS 制剂方面的生理物种特异性差异,可影响剂型在体性能在动物和人类之间。此外,它也是重要的结合体外特性与计算机模型来预测在体性能在人类中精确。在这篇综述文章,我总结了体外-计算机模拟方法来预测口服 DDS 制剂(无定形固体分散体,基于脂质的制剂,纳米制剂,基于环糊精的制剂,缓释产品,肠溶包衣产品,和口服崩解片)和注射用 DDS 制剂(基于环糊精的制剂,脂质体,和吸入制剂)的体内性能。